Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:\nOppenheimer Rare and Orphan Disease Summit.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, May 14, 2021
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Life sciences, Medical specialties, Clinical medicine, Complement deficiency, Biotechnology, Angioedema, Catabasis Pharmaceuticals, Hereditary angioedema, Monoclonal antibody, Biopharmaceutical, QLS, Kallikrein
Geotags: 
United States, Massachusetts
⚠ generated by AI ↴
Organisation: 
CATABASIS
Summary
Key Points: 
  • b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:\nOppenheimer Rare and Orphan Disease Summit.
  • Presentations will be available on-demand on May 21, 2021.\nJefferies Virtual Healthcare Conference on June 3, 2021 at 9:30am ET.\nWebcasts of the events can be accessed from the investors section of www.catabasis.com .
  • Archived replays will be available for 30 days following the event.\nAt Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005065/en/\n'


Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:

  • Oppenheimer Rare and Orphan Disease Summit. Presentations will be available on-demand on May 21, 2021.
  • Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30am ET.

Webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will be available for 30 days following the event.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Copyright: 
Copyright Business Wire 2021